申请人:Abbott Laboratories
公开号:US06307047B1
公开(公告)日:2001-10-23
The present invention describes pyridazinone compounds of formula I
which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important “housekeeping” enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).
该发明描述了式I的吡啶并酮化合物,这些化合物是环氧合酶(COX)抑制剂,特别是选择性地抑制环氧合酶-2(COX-2)。COX-2是与炎症相关的可诱导异构体,与构成性异构体环氧合酶-1(COX-1)相对,后者是许多组织中重要的“基础”酶,包括胃肠道(GI)和肾脏。这些化合物对COX-2的选择性减少了目前市售的非甾体类抗炎药(NSAIDs)所见到的不良胃肠道和肾脏副作用。